论文部分内容阅读
Amylin制药公司和礼来公司共同研发的2型糖尿病治疗药exenatide(商品名:Byetta)注射液近日获得美国FDA批准,与甘精胰岛素联合用于对单独使用甘精胰岛素时不能充分控制血糖的2型糖
The extenatide (trade name: Byetta) injection, a type 2 diabetes treatment jointly developed by Amylin Pharmaceuticals and Eli Lilly and Company, was recently approved by the U.S. Food and Drug Administration (FDA) for use in combination with insulin glargine to not adequately control glycemia when insulin glargine is used alone Sugar